STERIS (NYSE:STE) Releases Earnings Results

STERIS (NYSE:STE) announced its quarterly earnings data on Wednesday. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts’ consensus estimates of $2.33 by ($0.01), Zacks reports. STERIS had a net margin of 8.02% and a return on equity of 13.78%. STERIS updated its FY 2025 guidance to 9.050-9.150 EPS.

STERIS Stock Performance

Shares of STE traded down $3.20 during mid-day trading on Friday, hitting $222.24. 91,360 shares of the company’s stock were exchanged, compared to its average volume of 494,966. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33. STERIS has a fifty-two week low of $197.82 and a fifty-two week high of $248.24. The business’s 50 day moving average is $212.33 and its two-hundred day moving average is $224.59. The firm has a market capitalization of $21.94 billion, a P/E ratio of 50.85 and a beta of 0.84.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be given a $0.57 dividend. The ex-dividend date is Thursday, February 20th. This represents a $2.28 annualized dividend and a yield of 1.03%. STERIS’s dividend payout ratio (DPR) is 52.05%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on STE shares. Piper Sandler lifted their price target on STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday. StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. JMP Securities reiterated a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research note on Thursday. Stephens restated an “overweight” rating and set a $240.00 price objective on shares of STERIS in a research report on Thursday. Finally, Needham & Company LLC restated a “hold” rating on shares of STERIS in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $258.75.

Insider Activity at STERIS

In other news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the sale, the senior vice president now owns 11,372 shares of the company’s stock, valued at $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.14% of the stock is currently owned by insiders.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.